Stockscreener 앱 받기
10.95
1.71%
-0.19
시장 영업 전:
11.47
0.52
+4.75%
전일 마감가:
$11.14
열려 있는:
$11.2
하루 거래량:
628.78K
Relative Volume:
1.44
시가총액:
$1.47B
수익:
$53.99M
순이익/손실:
$-222.30M
주가수익비율:
-6.0277
EPS:
-1.8166
순현금흐름:
$-213.50M
1주 성능:
-5.52%
1개월 성능:
+5.80%
6개월 성능:
+22.48%
1년 성능:
+114.71%
1일 변동 폭
$10.86
$11.53
1주일 범위
$10.56
$11.65
52주 변동 폭
$3.94
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
10.95 | 1.47B | 53.99M | -222.30M | -213.50M | -1.8166 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-05-28 | 개시 | Deutsche Bank | Buy |
| 2024-10-07 | 개시 | Piper Sandler | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2020-11-20 | 개시 | BofA Securities | Buy |
| 2020-09-22 | 개시 | Goldman | Buy |
| 2020-07-27 | 개시 | SVB Leerink | Outperform |
| 2020-07-24 | 개시 | Jefferies | Buy |
모두보기
Immatics N V 주식(IMTX)의 최신 뉴스
Immatics (IMTX) to Release Quarterly Earnings on Tuesday - MarketBeat
TD Cowen initiates coverage of Immatics NV (IMTX) with buy recommendation - MSN
Immatics (NASDAQ:IMTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Immatics NV Stock Operating Data - GuruFocus
Immatics NV (HAM:4A3) Cyclically Adjusted PS Ratio : (As of May. 01, 2026) - GuruFocus
Immatics NV (HAM:4A3) Stock News, Headlines & Updates - GuruFocus
Operating cash flow per share of Immatics N.V. – MUN:4A3 - TradingView
Net current asset value per share of Immatics N.V. – MUN:4A3 - TradingView
IMTX Initiates Coverage On TD Cowen -- Rating Set to Buy - GuruFocus
TD Cowen initiates Immatics stock coverage with buy rating By Investing.com - Investing.com India
TD Cowen initiates Immatics stock coverage with buy rating - Investing.com
(IMTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
IMTX: Jefferies Analyst Biren Amin Rates Immatics with a "Buy" and Sets Price Target at $18.00 | IMTX Stock News - GuruFocus
Immatics announces four oral presentations at ASCO meeting By Investing.com - Investing.com Australia
Immatics Secures Four High-Profile Oral Slots for PRAME and Bispecific Programs at 2026 ASCO - TipRanks
Immatics announces four oral presentations at ASCO meeting - Investing.com
Immatics (NASDAQ: IMTX) lines up four oral cancer therapy talks for ASCO 2026 - Stock Titan
Immatics Announces Four Upcoming Oral Presentations Across - GlobeNewswire
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting - ChartMill
Four cancer studies put Immatics’ cell therapies on ASCO stage - Stock Titan
Immatics NV stock (NL0015255052): Is its TCR-T cell platform strong enough to unlock biotech upside? - AD HOC NEWS
Immatics NV stock (NL0015255052): Is its TCR-T cell therapy platform strong enough to unlock biotech - AD HOC NEWS
Immatics (IMTX) Is Up 7.1% After Pediatric PRAME TCR Remission Case And AACR SpotlightHas The Bull Case Changed? - Sahm
Steffen Martin Walter Net Worth (2026) - GuruFocus
Immatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma - Sahm
Amie Elizabeth Krause Net Worth (2026) - GuruFocus
Immatics (IMTX) Showcases Pediatric Patient Breakthrough at AACR 2026 - GuruFocus
PRAME-directed Cell Therapy Using Immatics' TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma - Investing News Network
Immatics Highlights PRAME-Targeted Cell Therapy Remission in Pediatric Kidney Cancer, Plans Pediatric Trial Expansion - TipRanks
Pediatric remission case for Immatics (NASDAQ: IMTX) PRAME cell therapy - Stock Titan
PRAME-directed Cell Therapy Using Immatics’ TCR Induces - GlobeNewswire
Jordan Zeik Silverstein Net Worth (2026) - GuruFocus
Cedrik Michael Britten Net Worth (2026) - GuruFocus
Sturchio Edward A Jr Net Worth (2026) - GuruFocus
Toni Michael Weinschenk Net Worth (2026) - GuruFocus
Reinhardt Carsten Alexander Johannes Net Worth (2026) - GuruFocus
Price-Driven Insight from (IMTX) for Rule-Based Strategy - Stock Traders Daily
ETF Watch: Can Immatics NV Equity Warrant generate free cash flow2026 Sentiment & Weekly Stock Breakout Alerts - baoquankhu1.vn
Exit Recap: Is Immatics NV currently under institutional pressure2026 Momentum & Capital Protection Trade Alerts - baoquankhu1.vn
Take Profit: Is Immatics NV forming a breakout pattern2026 News Drivers & Weekly High Conviction Ideas - baoquankhu1.vn
Risk Analysis: Should I invest in Immatics NV Equity Warrant before earningsEarnings Beat & Accurate Entry/Exit Alerts - baoquankhu1.vn
What do insiders think about Immatics N.V. (IMTX) Stock | Price at $10.32, Up 0.68%Trending Entry Points - Newser
(IMTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
SG Americas Securities LLC Makes New Investment in Immatics N.V. $IMTX - MarketBeat
IMTX Technical Analysis & Stock Price Forecast - Intellectia AI
Is Immatics (IMTX) Building a PRAME-Focused Platform or Stretching Its Oncology Ambitions Too Thin? - Sahm
IMTX Stock Analysis: Immatics N.V. Ordinary Shares rises 3.4 percent to 10.35 in biotech uptrend - Newser
What is the sentiment around Immatics N.V. (IMTX) Stock | Price at $10.35, Up 3.40%Retail Money Flow - Newser
Aug Technicals: Should I invest in Immatics NV Equity Warrant before earnings2026 PostEarnings & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Retail Trends: Should you buy the dip on Immatics NV2026 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Immatics N V (IMTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):